Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 26;2(2):913-54.
doi: 10.3390/cancers2020913.

Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies

Cécile Le Page  1 , David G Huntsman, Diane M Provencher, Anne-Marie Mes-Masson
Affiliations

Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies

Cécile Le Page et al. Cancers (Basel). .

Abstract

Epithelial ovarian cancer is the most lethal gynecological malignancy. Due to its lack of symptoms, this disease is diagnosed at an advanced stage when the cancer has already spread to secondary sites. While initial rates of response to first treatment is >80%, the overall survival rate of patients is extremely low, mainly due to development of drug resistance. To date, there are no reliable clinical factors that can properly stratify patients for suitable chemotherapy strategies. Clinical parameters such as disease stage, tumor grade and residual disease, although helpful in the management of patients after their initial surgery to establish the first line of treatment, are not efficient enough. Accordingly, reliable markers that are independent and complementary to clinical parameters are needed for a better management of these patients. For several years, efforts to identify prognostic factors have focused on molecular markers, with a large number having been investigated. This review aims to present a summary of the recent advances in the identification of molecular biomarkers in ovarian cancer patient tissues, as well as an overview of the need and importance of molecular markers for personalized medicine in ovarian cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Brief schematic representation of cell cycle regulation.
Figure 2
Figure 2
Brief schematic representation of intrinsic and extrinsic apoptotic pathways.
Figure 3
Figure 3
Role of hypoxia in tumor angiogenesis.
See this image and copyright information in PMC

References

    1. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 2001;22:255–288. doi: 10.1210/er.22.2.255. - DOI - PubMed
    1. Levanon K., Crum C., Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 2008;26:5284–5293. doi: 10.1200/JCO.2008.18.1107. - DOI - PMC - PubMed
    1. Lynch H.T., Casey M.J., Snyder C.L., Bewtra C., Lynch J.F., Butts M., Godwin A.K. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol. Oncol. 2009;3:97–137. doi: 10.1016/j.molonc.2009.02.004. - DOI - PMC - PubMed
    1. Gilks C.B., Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum. Pathol. 2009;40:1213–1223. doi: 10.1016/j.humpath.2009.04.017. - DOI - PubMed
    1. Chuaqui R.F., Cole K.A., Emmert-Buck M.R., Merino M.J. Histopathology and molecular biology of ovarian epithelial tumors. Ann. Diag. Patho.l. 1998;2:195–207. doi: 10.1016/S1092-9134(98)80007-5. - DOI - PubMed

LinkOut - more resources